Andere Sprachen Acrivon Therapeutics, Inc.

Aktien

A3DXE7

US0048901096

ACRV

Realtime-Estimate Cboe BZX Andere Börsenplätze 17:21:30 23.05.2024			% 5 Tage	% 1. Jan.
8,27 ^USD	-3,50 %		-3,39 %	+68,09 %

14.05.	Acrivon Therapeutics, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
29.04.	ACRIVON THERAPEUTICS, INC. : Ladenburg Thalmann bekräftigt seine neutrale Bewertung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights	14.05.
Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
North American Morning Briefing : More Earnings -2-	30.04.
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event	24.04.
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress At Corporate R&D Event	24.04.
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316	17.04.
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368	10.04.
Top Midday Gainers	09.04.
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	09.04.
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday on Caution Ahead of Inflation Data	09.04.
Acrivon Therapeutics Announces Private Placement of 8.2 Million Shares; Shares Surge	09.04.
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell	09.04.
Top Premarket Gainers	09.04.
Acrivon Therapeutics Announces $130 Million Private Placement Financing	09.04.
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	28.03.
Acrivon Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.03.
Acrivon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316	05.03.
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors	04.03.
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors	04.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Acrivon Therapeutics, Inc.

Aktien

A3DXE7

US0048901096

ACRV

Andere Sprachen

Filter